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Background: The role of iPLA2 as a regulator of inflammatory signaling and neointima formation is unknown.
Results: Smooth muscle-specific expression of iPLA2 exacerbates proinflammatory cytokine production, macrophage infil-
tration, and neointima formation.
Conclusion: Smooth muscle-specific iPLA2 participates in the initiation and early progression of vascular inflammation and
neointima formation.
Significance: iPLA2 may represent a novel therapeutic target for attenuating vascular inflammation and restenosis.
Whether groupVIA phospholipaseA2 (iPLA2) is involved in
vascular inflammation and neointima formation is largely
unknown. Here, we report that iPLA2 expression increases in
the vascular tunica media upon carotid artery ligation and that
neointima formation is suppressed by genetic deletion of
iPLA2 or by inhibiting its activity or expression via perivascu-
lar delivery of bromoenol lactone or of antisense oligonucleo-
tides, respectively. To investigate whether smooth muscle-spe-
cific iPLA2 is involved in neointima formation, we generated
transgenic mice in which iPLA2 is expressed specifically in
smooth muscle cells and demonstrate that smooth muscle-spe-
cific expression of iPLA2 exacerbates ligation-induced
neointima formation and enhanced both production of proin-
flammatory cytokines and vascular infiltration bymacrophages.
With cultured vascular smooth muscle cell, angiotensin II,
arachidonic acid, and TNF- markedly induce increased
expression of IL-6 and TNF- mRNAs, all of which were sup-
pressed by inhibiting iPLA2 activity or expression with bro-
moenol lactone, antisense oligonucleotides, and genetic dele-
tion, respectively. Similar suppression also results from genetic
deletion of 12/15-lipoxygenase or inhibiting its activity with
nordihydroguaiaretic acid or luteolin. Expression of iPLA2
protein in cultured vascular smooth muscle cells was found to
dependon the phenotypic state and to rise upon incubationwith
TNF-. Our studies thus illustrate that smoothmuscle cell-spe-
cific iPLA2 participates in the initiation and early progression
of vascular inflammation and neointima formation and suggest
that iPLA2 may represent a novel therapeutic target for pre-
venting cardiovascular diseases.
Neointima formation is a common feature of restenosis after
balloon angioplasty, transplantation of vessels and organs, cor-
onary artery bypass grafting, percutaneous transluminal coro-
nary angioplasty, and atherosclerosis (1–5). Neointima forma-
tion has been extensively studied because of itsmultiple clinical
implications. The persistently high rates of restenosis after vas-
cular interventions indicate that the current understanding of
the molecular mechanisms responsible for neointima forma-
tion is incomplete, however, and the clinical significance of
neointima formation calls for identification of new therapeutic
targets.
The vascular smoothmuscle cell (VSMC)3 is a major cellular
component of the blood vessel wall, and its primary physiolog-
ical functions are to maintain homeostasis of blood flow and
blood pressure within normal ranges. In healthy mature blood
vessels, the VSMC exhibits a quiescent contractile phenotype
and expresses a unique repertoire of smoothmuscle contractile
proteins. Upon various injurious stimuli, theVSMCdedifferen-
tiates, rapidly switches from a contractile phenotype to a syn-
thetic phenotype, and migrates from the medial to the intimal* This work was supported, in whole or in part, by National Institutes of Health
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layer of the vessel wall where it proliferates to form neointima
(1–6). In addition tomigration and proliferation, VSMCwith a
synthetic phenotype can produce various proinflammatory
cytokines in vitro and in vivo (7–9). Paradoxically, the initiation
and early progression of vascular inflammation in restenosis
has been attributed largely to interactions amongmacrophages,
lymphocytes, and endothelial cells (1–5), despite the fact that
the large number of VSMC in the vessel wall are capable of
producing significant amounts of cytokines that could contrib-
ute to the evolution of the inflammatory process.
Phospholipases A2 (PLA2) comprise a family of enzymes that
hydrolyze esterified fatty acid residues from the sn-2 position of
glycerophospholipids to produce a free fatty acid (e.g. arachi-
donic acid (AA)) and a lysophospholipid (e.g. 1-radyl, 2-lyso-
glycerophosphocholine (LPC)) (10). Based on their cellular
location and the Ca2 requirement for enzymatic activity,
PLA2s are classified into three subfamilies as follows: secretory
PLA2, cytosolic PLA2, and calcium-independent PLA2 (iPLA2).
The iPLA2 enzymes recognized so far are located within cells,
do not require Ca2 for enzymatic activity, and are subject to
irreversible inhibition by the suicide substrate bromoenol lac-
tone (BEL) at concentrations that do not inhibit secretory PLA2
or cytosolic PLA2 enzymes (11).
The iPLA2 enzymes are also members of a larger family of
lipases designated the patatin-like phospholipase domain-con-
taining proteins (PNPLA), of which the human genome
expresses nine members (PNPLA1–9) (12). PNPLA family
members contain a protein domain discovered initially in pata-
tin, which is a lipid hydrolase that is the most abundant protein
of the potato tuber. Mammalian PNPLAs include lipid hydro-
lases with specificities for diverse substrates such as triacylglyc-
erols, phospholipids, and retinol esters. PNPLA9 corresponds
to group VIA PLA2 (iPLA2), and its recognition predates that
of the PNPLA family as a whole. Of the iPLA2 enzymes, iPLA2
was the first recognized, the most extensively studied, and the
best characterized member. iPLA2 is ubiquitously expressed
and is distributed mainly in cytoplasm under resting condi-
tions, but upon cellular stimulation, it can translocate to mem-
branous organelles where it hydrolyzes phospholipids to gen-
erateAA and LPC (13, 14), among other products. BothAA and
LPC have intrinsic second messenger functions in some set-
tings, can also bemetabolized into diverse bioactive lipidmedi-
ators, and have been implicated in a variety of physiopatholog-
ical processes (15).
We and others have shown that iPLA2 is expressed in cul-
tured VSMC in vitro and in blood vessels in vivo (16–20), that
iPLA2 enzymatic activity increases upon incubating VSMC
with angiotensin II (Ang II), vasopressin, thrombin, and high
concentrations of glucose in culture (16, 17, 20–22), and that
agonist-induced release of free AA fromVSMC is largely medi-
ated by iPLA2 (21–23). Moreover, smoothmuscle iPLA2 has
been functionally implicated in Ca2 influx (18), proliferation
(17, 23), transcriptional regulation (16, 24), Ca2 sensitization
of smooth muscle contraction (19), and diabetes-associated
vascular hypercontractility (20).
Whether iPLA2 plays a role in vascular inflammation and
neointima formation has so far not been examined in any ani-
malmodels of whichwe are aware. Here, we report that smooth
muscle cell-specific iPLA2 responds to vascular injury and
participates in the initiation and early progression of vascular
inflammation and neointima formation in a murine carotid
artery ligation model.
EXPERIMENTAL PROCEDURES
Materials and Animals—The antibody against iPLA2 was
generated in our laboratory as described previously (16, 20).
The antibodies against smoothmuscle cell-actin (SMA) and
FLAGwere purchased from Sigma. The antibody against CD31
was purchased from BD Biosciences. The antibody against
F4/80 was purchased from AbD Serotec (Raleigh, NC). The
antibody against -actin and PCNA was purchased from Cell
Signaling (Danvers,MA). The antibody against cPLA2 was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). The
antibodies against IL-6 and NFB p65 were purchased from
Abcam (Cambridge, MA). The antibody against TNF- was
purchased from IHC World (Woodstock, MD). Recombinant
mouse TNF- was purchased from R&D Systems (Minneapo-
lis, MN). BEL, 17-octadecynoic acid, MK886, baicalein, and
luteolin were purchased from Cayman (Ann Arbor, MI). Nor-
dihydroguaiaretic acid and indomethacin were purchased from
Biomol (Plymouth Meeting, PA). Other chemicals and materi-
als were purchased from Sigma or Fisher unless indicated
otherwise.
C57BL/6 and 12/15-lipoxygenase-null mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). The iPLA2-
null mice were generated in the laboratory of Dr. John Turk, as
described elsewhere (25). All animals used in this study were
8–10-week-old male mice. All animal studies were performed
in accordance with the “Guidelines for the Care and Use of
Experimental Animals,” American Association for Accredita-
tion of Laboratory Animal Care, and were approved by the
Institutional Animal Care andUseCommittee at theUniversity
of Kentucky.
Cloning of Rabbit Smooth Muscle Myosin Heavy Chain Pro-
moter andMouse iPLA2 Promoter—Nested PCR was used for
cloning of the rabbit smooth muscle myosin heavy chain
(SMMHC) promoter. Briefly, the first pair of external primers
(rabbit SMMHC-MluI-F1 and rabbit SMMHC-SpeI-R1, see
supplemental Table 1) was used to amplify a 2,305-bp rabbit
SMMHC promoter from the rabbit brain genomic DNA. The
second pair of internal primers (rabbit SMMHC (2251)-F2,
rabbit SMMHC (18)-R2, see supplemental Table 1) was used
to amplify a 2,234-bp fragment (2,251 to 18 bp relative to
the transcription start site) using the first PCR product as a
template. The 2,234-bp PCR product was sequenced and found
to be almost identical to the published rabbit SMMHC pro-
moter sequence (26). A 14-mer oligonucleotide corresponding
to the17 to4 bp of the rabbit SMMHCpromoterwas added
to the 3-end of the 2,234-bp fragment by PCR to generate a
2,248-bp rabbit SMMHC promoter (2251 to 4 bp).
A mouse bacterial artificial chromosome clone (RP23-
300M4) containing iPLA2 gene was purchased from Invitro-
gen and used as PCR template. A 0.952-kb PCR fragment
(1,411 bp to 459 bp relative to the translational start site)
containing a predicated iPLA2 promoter (1,278 to 460 bp,
analyzed by Genomatix MatInspector software) was amplified
iPLA2, Vascular Inflammation, and Neointima Formation
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by PCR using a pair of primers (supplemental Table 1). After
verification by DNA sequencing, this putative 0.952-kb iPLA2
promoter was subcloned into a pGL3 basic vector (Promega,
Madison, WI) at KpnI and XhoI sites to generate iPLA2 pro-
moter-Luc reporter.
Generation of Smooth Muscle-specific iPLA2 Transgenic
Mice—Four sequential steps were taken to construct a smooth
muscle- specific transgenic vector as described below. First, an
additional 28-mer (3 to 25 bp) oligonucleotide containing
the rabbit SMMHC transcriptional start site was added to the
3-end of 2,248-bp SMMHC promoter by PCR to generate a
2,276-bp SMMHC promoter (2251 to 25 bp). Second, a
NotI enzyme site in pCI vector (Promega, Madison, WI) was
removed by NotI and SmaI enzyme digestion followed by large
(Klenow) fragment of DNA polymerase and blunt ligation. The
modified pCI vector was then cut by PstI and BamH1 to gener-
ate an 500-bp fragment containing a chimeric intron, a mul-
tiple cloning site, and a SV40 late poly(A). The 500-bp frag-
mentwas ligated into PCR-Blunt vector (Invitrogen) at PstI and
BamH1 enzyme sites to generate an “intermediate vector 1.”
Third, an 2,400-bp rat iPLA2 cDNA (19), containing a
Kozak sequences at its 5-end and a FLAG tag at its 3-end, was
amplified by PCR and then ligated into the intermediate vector
1 at NheI and SalI enzyme sites to generate an “intermediate
vector 2.” Finally, the 2,276-bp rabbit SMMHC promoter was
ligated into the “intermediate construct 2” at NotI and EcoRV
enzyme sites to generate an iPLA2 smooth muscle-specific
transgenic vector containing a rabbit SMMHCpromoter, a chi-
meric intron derived frompCI vector, a rat iPLA2-Flag cDNA,
and SV40 late poly(A) derived from pCI vector (Fig. 2A).
The iPLA2 smooth muscle-specific transgenic vector was
linearized by NsiI enzyme to remove the PCR-Blunt vector
backbone. The linear DNA fragment was microinjected into
zygotes from B6C3F1 mice (Harlan Laboratories, Indianapolis,
IN) by the University of Kentucky Transgenic Mouse Facility.
Pups derived from the microinjected embryos were screened
for the presence of the iPLA2 transgene by mouse tail geno-
typing PCR using two sets of primers (supplemental Table 1) as
follows: the first set of primers, Trans-iPLA2-up and Trans-
iPLA2-down, was used to amplify a fragment from the 3-end of
iPLA2 to the 5-endof the FLAG tag; the second set of primers,
MHCP-Intron-F1 and iPLA2-R1, was used to amplify a frag-
ment from 3-end of a chimeric intron to 5-end of iPLA2.
Seven independent founders were identified to be positive to
both sets of PCR screenings. Pups derived from the seven
founders were further subjected toWestern blot using an anti-
FLAG mAb. Three of seven founders were found expressing
iPLA2-FLAG tag protein in vascular smooth muscle tissues.
Based upon levels of iPLA2 protein expression and iPLA2
enzymatic activity (data not shown), two independent founders
with different levels of exogenous iPLA2 were retained in the
laboratory and were backcrossed with C57BL/6J mice at least
eight generations for the current studies.
Murine Carotid Artery Complete Ligation Model—Mice
were anesthetizedwith an intraperitoneal injection of ketamine
(100 mg/kg) and xylazine (10 mg/kg) in sterile saline. The
carotid arteries were exposed through a small midline incision
in the neck. The left common artery was ligated with a 5-0
suture just near its bifurcation to completely disrupt the blood
flow (27). The right common carotid artery was used as a sham-
operated control by passing the same suture below without
ligation.
Local Administration of BEL or Antisense Oligonucleotide to
Carotid Artery by Pluronic Gel—We used pluronic gel, an
established local drug delivery method (28), to deliver BEL or
antisense oligonucleotide to the carotid artery to inhibit
iPLA2 and avoid potential systemic side effects. BEL or vehicle
(Me2SO2) was mixed with 30% F-127 pluronic gel at 4 °C. The
final concentration of BEL in pluronic gel was 91 M. iPLA2
antisense or sense oligonucleotide was mixed with Lipo-
fectamine 2000 reagent (Invitrogen) and then suspended in
30% F-127 pluronic gel at 4 °C. The final concentration of Lipo-
fectamine 2000 reagent and oligonucleotides was 1% and 50
g/ml, respectively. Immediately after left carotid artery liga-
tion, 200 l of F-127 pluronic gel containing BEL or vehicle or
100 l of F-127 pluronic gel containing antisense or sense oli-
gonucleotides were distally applied to the external surface of
the carotid artery relative to the ligation site.
Morphometric Analysis—At 3 or 28 days after carotid artery
ligation,mice were euthanized and perfused with PBS for 5min
followed by Formalde-Fresh solution (Fisher) for 30 min
through the left ventricle under physiological pressure. The
perfusion-fixed left carotid arterieswere excised and embedded
in paraffin orTissue-TekOCTcompound. Serial 5-mparaffin
cross-sections or 10mcross-cryosectionswere obtained from
each mouse, which covers 500–2,500 m of carotid artery rel-
ative to the ligation site. Cross-sections were stained with the
Elastic Stain kit (Fisher) or hematoxylin and eosin. All stained
sections were photographed by an Olympus IX70 microscope
equipped with Olympus DP70 digital camera. The circumfer-
ence of the lumen, the internal elastic lamina, and the external
elastic lamina were determined by Olympus MicroSuitTM-B3
software. The areas surrounded by the luminal surface, internal
elastic lamina, and external elastic lamina were then calculated.
The neointimal area was calculated by subtracting the lumen
area from the area inside the internal elastic lamina. Themedial
area was calculated by subtracting the area inside the internal
elastic lamina from the area inside the external elastic lamina.
Immunocytochemistry—Paraffin cross-sections were depar-
affinized with xylene and rehydrated in a graded ethanol series
and unmasked by antigen unmasking solution (Vector Labora-
tories, Burlingame, CA) or proteinase K (Invitrogen). Endoge-
nous peroxidaseswere quenched by 3%hydrogen peroxide, and
nonspecific binding sites were blocked by using an avidin/bio-
tin blocking kit (Vector Laboratories), followed by 10% normal
goat serum. Slides were incubated with the following concen-
trations of primary antibodies overnight at 4 °C: anti-iPLA2
Ab (1:5,000 dilution), anti-FLAG Ab (1:100 dilution), anti-IL-6
Ab (1:800 dilution), anti-TNF- Ab (no dilution), anti-NFB
P65 Ab (1:4,000 dilution), anti-F4/80 Ab (1:50 dilution), and
anti-PCNA Ab (1:16,000 dilution). Slides were then subjected
to the procedure of Vectastain Elite ABC system (Vector Lab-
oratories). Immunoreactivity was visualized by 3,3-diamino-
benzidine (DAKO North America Inc., Carpinteria, CA) or 3-
amino-9-ethyl carbazole (Biomeda Corp., Foster City, CA),
followed by counterstaining with hematoxylin.
iPLA2, Vascular Inflammation, and Neointima Formation
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Western Blot Analysis—To obtain sufficient amount of pro-
teins for immunoblotting, the ligated or nonligated carotid
arteries from twomicewere pooled for one sample preparation.
Carotid arteries were frozen with liquid nitrogen and subjected
toWestern blot analysis as described previously (16, 19, 20, 24,
29–32).
Real Time PCR—Primer sequences used for quantification of
mRNA levels frommouse carotid arteries by real time PCR are
listed in supplemental Table 1 except for 18 S rRNA that has
been described previously (16, 20, 24, 29, 33). The procedures of
real time PCR were described previously (16, 20, 24, 29, 33).
iPLA2 Promoter Activity Analysis—2- or 9-passage rat aor-
tic VSMCwere grown in 12-well cell culture plates. When they
achieved 70–80% confluence, cells were co-transfectedwith an
iPLA2-Luc reporter and pRL-TK vector (Promega) using
Lipofectamine-Plus reagent. iPLA2 promoter activity was
analyzed as described previously (24).
iPLA2 Assay—The iPLA2 activity was assayed using 14C-la-
beled 1-palmitoyl-2-[1-14C]palmitoyl-sn-glycero-3-phosphor-
ylcholine (GE Healthcare), as described previously (19), or
using arachidonoyl thio-PC as described previously (16, 20).
Primary VSMC Culture—The procedure for isolation and
culture of primary aortic VSMC frommaleNewZealandWhite
rabbits, Sprague-Dawley rats, iPLA2-null mice, 12/15 lipoxy-
genase-null mice, and wild-type littermates was described pre-
viously (16, 19, 20, 24, 29–32). The usage of cultured rabbit, rat,
and mouse VSMC was specifically indicated under the
“Results” and in the figure legends.
Statistical Analysis—Each experiment was repeated inde-
pendently at least three times. Data were expressed as mean 
S.E. Statistical analysis was performed by using unpaired t
tests for two groups and one- or two-way analysis of variance
with repeated measurement for multiple groups (GraphPad
Prism 4).
RESULTS
iPLA2 Up-regulation in Response to Carotid Artery Liga-
tion Precedes Neointima Formation—To determine whether
iPLA2 participates in neointima formation, we first exam-
ined iPLA2 protein expression in a widely used model of
vascular injury that involves ligation of the carotid artery
(27). Immunoblotting analyses with our recently developed
iPLA2 antibody (16) revealed a substantial increase in
expression of iPLA2 protein in carotid arteries at 28 days
after ligation compared with that in nonligated vessels from
control mice (Fig. 1, A and B).
To examine the temporal relationship of increased expres-
sion of iPLA2 protein and formation of neointima in response
to carotid artery ligation, the arteries were isolated at 3 days
after ligation and subjected to immunostaining analyses with
our iPLA2 antibody. No neointima was observed 3 days after
ligation, but increased expression of iPLA2 protein was clearly
apparent in the tunica media of ligated vessels compared with
that in nonligated vessels (supplemental Fig. 1A). To identify
the cells responsible for increased expression of iPLA2 pro-
tein, immunostaining of carotid arteries 3 days after ligation
was performed with our iPLA2 antibody and antibodies
directed against markers for smooth muscle cells, for endothe-
lial cells, and for macrophages. The supplemental Fig. 1B illus-
trates that iPLA2 largely co-localized with the smooth muscle
FIGURE 1. iPLA2 is up-regulated in carotid artery by ligation and inhibition of iPLA2 with BEL, antisense oligonucleotide, and genetic deletion
attenuates neointima formation. Ligated (injury) and nonligated (sham) carotid arteries were isolated from C57BL/6J mice at 3 days (C), 14 days (F and G), or
28 days (A and B, D and E, and H and I) after ligation and then subjected to Western blot analysis (A and B), real time PCR (C), or morphometric analysis (D–I).
A, representative Western blots (each sample represents carotid arteries from two mice). B, summary of Western blot results shown in A (n  5). C, summary of
real time PCR results (n  7). D and E, summary of neointimal area (D) and neointimal/medium ratio (E) from four pairs of mice that were perivascularly treated
with BEL or vehicle (Me2SO2). F and G, summary of neointimal area (F) and neointimal/medium ratio (G) from nine pairs of mice that were perivascularly treated
with iPLA2 antisense or sense oligonucleotides. H and I, summary of neointimal area (H) and neointimal/medium ratio (I) from 10 pairs of iPLA2-null mice
and WT littermates. Results are expressed as mean  S.E. of four cross-sections that are 200 m apart and cover 1,000 –1,600 m (D–G) and 1,000 –1,400 m
(H and I) along the carotid artery from the ligation site. *, p  0.05; **, p  0.01; ***, p  0.001.
iPLA2, Vascular Inflammation, and Neointima Formation
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marker -actin (SMA). Lesser amounts of iPLA2were found
to co-localize with the endothelial cell marker CD31 and the
macrophage marker F4/80 (supplemental Fig. 1, C and D).
These results indicate that increased expression of iPLA2 pro-
tein precedes neointima formation and may arise mainly from
resident VSMC rather than from endothelial cells or
macrophages.
To investigate the mechanism by which carotid artery liga-
tion leads to increased iPLA2 protein expression, we exam-
ined iPLA2mRNA levels by real time PCR, andwe found them
to be increased in carotid arteries 3 days after ligation (Fig. 1C),
which may account in part for the increased expression of
iPLA2 protein.
Inhibiting iPLA2 Activity or Expression by Perivascular
Delivery of BEL or Antisense Oligonucleotides, Respectively,
Suppresses Neointima Formation Induced by Carotid Artery
Ligation, as Does Genetic Deletion of iPLA2—To determine
whether increased iPLA2 expression after carotid artery liga-
tion plays a causal role in neointima formation, the iPLA2
inhibitor BEL (11) was delivered into the perivascular space in
thermoreversible F127 pluronic gel (supplemental Fig. 1E) (28).
The BEL concentration in the gel was 91 M, but release of
inhibitors from pluronic gel is a continuous and relatively slow
process (28). The effective concentration of BEL that enters the
carotid artery in vivo under these conditions is thus probably
comparable with that used in vitrowith culturedVSMC (16, 17,
20–22). Carotid arteries were isolated 28 days after ligation and
sliced in serial sections to determine the effect of BEL on
neointima formation (supplemental Fig. 1F). Representative
images of Verhoeff-VanGieson staining (supplemental Fig. 1G)
and quantitative data indicate that perivascular delivery of BEL
resulted in significant reduction of the neointimal area (Fig. 1D)
and of the ratio of the neointimal area to the medial area (Fig.
1E).
BEL inhibits all iPLA2 isoforms (34), and any of them (e.g.
iPLA2 versus iPLA2) might account for the effect of BEL to
suppress neointima formation. BEL may also inhibit other
unrecognized targets (35).We therefore examined the effects of
an iPLA2 antisense oligonucleotide that we and others have
previously demonstrated to selectively suppress iPLA2 pro-
tein expression and function effectively in cultured VSMC in a
selective manner (16–18, 24). Antisense oligonucleotide is
completely released from pluronic gel after 3 days (28), and we
therefore harvested carotid arteries 14 days rather than 28 days
after ligation to examine the effect of antisense oligonucleotide
on neointima formation. Less neointima formation was
observed 14 days after ligation compared with that at 28 days
after ligation (e.g. Fig. 1, D versus F). Nonetheless, the iPLA2
antisense oligonucleotide inhibited neointima formation in a
manner similar to BEL (Fig. 1, F and G; supplemental Fig. 1H).
These results suggest that iPLA2 may play a causal role in
neointima formation.
We also examined the effect of genetic deletion of iPLA2 on
neointima formation 28 days after carotid artery ligation. The
area of newly formed neointima in the wild-type (WT) litter-
mates of iPLA2-null mice was 3-fold lower than that in
C57BL/6J mice (e.g. Fig. 1, D versus H), which probably reflects
mouse strain differences because the iPLA2-null mice were
derived from 129/SvJmouse embryonic stem cells (25). 129/SvJ
mice are known to be more resistant to vascular injury
responses to carotid artery ligation than are C57B/6J mice (36).
Nonetheless, a significant decrease in neointimal area and in
the ratio of the neointimal area to themedial area was observed
for iPLA2-null mice compared with theirWT littermates (Fig.
1, H and I).
Development of a Novel Smooth Muscle-specific iPLA2
Transgenic MouseModel (SM-iPLA2-Tg)—Because iPLA2 is
ubiquitously expressed (13), it is unclear what cell type (e.g.
VSMC versus endothelial cell) expresses the pool of iPLA2
involved in neointima formation. To address this issue, we cre-
ated transgenic mice that overexpress iPLA2 specifically in
smooth muscle cells, which is similar to the increased iPLA2
expression that occurs in the media of the vascular wall in
response to carotid artery ligation (Fig. 1,A–C, and supplemen-
tal Fig. 1, A–D).
To create these mice, we cloned a 2,276-bp SMMHC pro-
moter from rabbit genomic DNA by nested PCR. Dual-Lucifer-
ase assay demonstrated that the cloned SMMHC promoter
activity in cultured VSMC was 8–10-fold higher than that in
cultured HeLa cells or GH3 cells (data not shown). As illus-
trated in Fig. 2A, the construct used to generate SM-iPLA2-Tg
mice is composed of a rabbit SMMHC promoter, a chimeric
intron, a full-length rat iPLA2 cDNA coding sequence, a
FLAG tag, and a poly(A) tail. Insertion of an intron between a
smoothmuscle-specific promoter and cDNA in transgenic vec-
tors has been shown to increase transgene expression (37).
Inclusion of a FLAG tag in the C terminus of iPLA2 allowed
exogenous and endogenous iPLA2 to be distinguishedwithout
interfering with iPLA2 function (16, 19, 20).
Three independent founder lines of SM-iPLA2-Tg mice
were obtained, and the one that exhibited the highest level of
iPLA2 expression was further characterized. First, to deter-
mine whether exogenous iPLA2 is expressed specifically in
smoothmuscle cells in SM-iPLA2-Tgmice, transgene expres-
sion in various tissues was examined by immunoblotting with
an anti-FLAG antibody. Fig. 2B illustrates that the FLAG-
iPLA2 fusion protein product of the transgene was detectable
only in smoothmuscle cell-enriched organelles, such as arteries
and colon. Interestingly, overexpression of exogenous iPLA2
in smooth muscle did not alter endogenous cPLA2 protein
expression in these tissues.
Second, to verify that the FLAG-iPLA2 fusion protein arises
only from smoothmuscle cells, we performed immunostaining
with an anti-FLAG antibody and observed that FLAG-express-
ing cells were readily apparent in the vascular smooth muscle
cell layers of coronary arteries, renal arteries, carotid arteries,
and aortas, in addition to the visceral smoothmuscle cell layers
of bladder, rectum, and ileum of the SM-iPLA2-Tg mice but
not control mice (supplemental Fig. 2).
Third, to examine the expression levels of iPLA2 from the
endogenous gene and from the transgene, immunoblotting was
performed with our iPLA2 antibody (16). Increased iPLA2
protein expression was observed in tissues of the transgenic
mice of at least 2.5-fold in aorta, 10-fold in mesenteric arteries,
and 2.3-fold in carotid arteries compared with WT littermates
(Fig. 2, C and D).
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Fourth, to determine whether iPLA2 protein arising from
the transgene is enzymatically active, wemeasured iPLA2 activ-
ity using a radiolabeled phospholipid substrate and following
release of the radiolabeled fatty acid product (19). The iPLA2-
specific activities in aorta and mesenteric arteries of
SM-iPLA2-Tg mice were found to be significantly greater
than those of WT littermates (Fig. 2E). These results are con-
cordant with those from the immunoblotting studies (Fig. 2, C
and D) and verify that iPLA2 that arises from the transgene is
enzymatically active.
Smooth Muscle-specific Expression of iPLA2 Exacerbates
Neointima Formation in Response to Carotid Artery Ligation—
To determine whether smooth muscle-specific expression of
iPLA2 affects neointima formation, we examined carotid
arteries from SM-iPLA2-Tg mice and WT littermates 28
days after ligation. No neointima was observed in either
SM-iPLA2-Tg mice or WT littermates in the absence of
carotid ligation (Fig. 3A). This result suggests that smoothmus-
cle-specific expression of iPLA2 is insufficient to induce
neointima formation. Therefore, only ligated carotid arteries
were subjected to quantitative analysis of neointima formation,
which revealed that smooth muscle-specific expression of
iPLA2 exacerbates ligation-induced increases in the neointi-
mal area (Fig. 3B) and in the ratio of the neointimal and total
area (Fig. 3C).
To determine whether smoothmuscle-specific expression of
iPLA2 affects vascular remodeling, we compared areas of the
lumen,media, and total vessel in SM-iPLA2-Tgmice and their
WT littermates at 28 days after carotid artery ligation. Smooth
muscle-specific expression of iPLA2 did not affect the luminal
area (supplemental Fig. 3A) but was associated with signifi-
cantly increased total vessel area andmedial area (supplemental
Fig. 3, B and C). This suggests that smooth muscle-specific
expression of iPLA2 causes positive (expansive) vascular
remodeling inwhich an increase in the neointimal area does not
necessarily result in a decrease in the luminal area due to simul-
taneous vessel enlargement (27, 38).
To exclude the possibility that the exacerbated neointima
formation in SM-iPLA2-Tg mice is due to a nonspecific ran-
dom insertion of the transgenic construct into chromosomes,
we analyzed neointima formation in a second line of
SM-iPLA2-Tg mice derived from a different founder with a
lower level of iPLA2 expression comparedwith that of the first
SM-iPLA2-Tg line studied. Similar results were obtained with
the second transgenic line (Fig. 3, D and E).
SmoothMuscle-specific Expression of iPLA2 Promotes Inflam-
matory Cytokine Production, Macrophage Infiltration, and
VSMC Proliferation in Response to Carotid Artery Ligation—
To gain insight into the mechanism by which smooth muscle
iPLA2 mediates neointima formation in response to carotid
FIGURE 2. iPLA2 is specifically expressed in smooth muscle cells in SM-iPLA2-Tg mice. A, schematic diagram of the DNA construct used for generation
of SM-iPLA2-Tg mice. B, representative Western blots of various tissues isolated from SM-iPLA2-Tg mice () and WT littermates (). C, representative
Western blots of aorta, mesentery artery (MA), and carotid artery (CA) isolated from SM-iPLA2-Tg mice (Tg) and WT littermates (WT). D, summary of Western
blots shown in C from 7 to 10 pairs of mice. E, summary of iPLA2 assay results (n  3). *, p  0.05; ***, p  0.0001 versus WT.
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artery ligation, we measured mRNA levels of proinflammatory
cytokines in carotid arteries fromSM-iPLA2-Tgmice andWT
littermates at 28 days after ligation. Fig. 4, A–D, illustrates that
smooth muscle-specific expression of iPLA2 exacerbated the
increase in mRNA levels for tumor necrosis factor- (TNF-),
interleukin-6 (IL-6), interleukin-1 (IL-1), and monocyte
chemotactic protein-1 (MCP-1) that occurred in response to
carotid artery ligation, although basal expression was unaf-
fected. Expression of RhoA (Fig. 4E) and ROCK2 (data not
shown) mRNA was also unaffected.
To examine effects of iPLA2 on initiation and early progres-
sion of vascular inflammation, we determined TNF- protein
expression in carotid arteries from SM-iPLA2-Tg mice and
WT littermates at 3 days after ligation. This time point was
selected because expression of iPLA2 increases at 3 days, but
neointima formation has not yet begun (supplemental Fig. 1A).
In nonligated vessels, little TNF- immunostaining was
detected for either SM-iPLA2-Tg mice or their WT litter-
mates (Fig. 4F). In contrast, a dramatic increase in TNF-
immunostaining was observed 3 days after carotid ligation in
both genotypes, and smooth muscle-specific expression of
iPLA2 amplified this increase. Similar effects were observed
with immunostaining for IL-6 (supplemental Fig. 4A).
The fact that smooth muscle-specific expression of iPLA2
affects expression of multiple proinflammatory cytokines (Fig.
4,A–F) suggests the possibility that iPLA2 might affect a mas-
ter regulator of inflammatory cytokine expression, such as
NFB. To test this possibility, we examined NFB p65 immu-
nostaining in carotid arteries from SM-iPLA2-Tg mice and
WT littermates at 3 days after ligation and found that theNFB
p65 immunostaining pattern (supplemental Fig. 4B) was simi-
lar to that of TNF- (Fig. 4F) and IL-6 (supplemental Fig. 4A).
To investigate whether increased proinflammatory cytokine
production by smooth muscle-specific expression of iPLA2
FIGURE 3. Smooth muscle-specific expression of iPLA2 exacerbates carotid ligation-induced neointima formation. Ligated (injury) and nonligated
(sham) carotid arteries were isolated from one line (A–C) or an independent line (D and E) of SM-iPLA2-Tg mice (Tg) and WT littermates (WT) at 28 days after
ligation and then subjected to morphometric analysis. A, representative photographs of Verhoef-Van Gieson staining. B–E, summary of neointimal area (B and
D) and neointimal/total ratio (C and E). Results were analyzed by two-way analysis of variance.
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might result in elaboration of chemotactic signals that attract
macrophagemigration into the lesion site, carotid arteries were
isolated from SM-iPLA2-Tg mice and WT littermates at 3
days after ligation. Macrophages were identified by F4/80
immunostaining and hematoxylin staining of their distinctive
large nuclei. In nonligated vessels, no macrophages were
observed in either SM-iPLA2-Tgmice or theirWT littermates
(Fig. 4G). In contrast, macrophages that had infiltrated the vas-
cular wall were readily detectable after carotid ligation, and it
was noteworthy that most of these macrophages were attached
to the vessel wall, although some were observed in the media
and adventitia of the vessels. This observation suggests that the
3-day time point represents an early stage in the process of
macrophage infiltration in which attachment to the vessel has
begunbut penetration into the vesselwall has just begun.None-
theless, substantially more macrophages were associated with
ligated vessels of SM-iPLA2-Tgmice comparedwith theirWT
littermates (Fig. 4H).
FIGURE 4. Effects of smooth muscle-specific expression of iPLA2 or genetic deletion of iPLA2 on carotid ligation-induced proinflammatory cytokine
production and macrophage infiltration. A–E, summary of real time PCR results in ligated (Injury) and nonligated (Sham) carotid arteries from SM-iPLA2-Tg
mice (Tg) and WT littermates (WT) at 28 days after ligation (n  3– 6). F, representative TNF- immunostaining of carotid artery cross-sections from Tg and WT
mice at 3 days after ligation. G, representative F4/80 immunostaining of carotid artery cross-sections from Tg and WT mice at 3 days after ligation. Attached
monocytes/macrophages were identified by F4/80-positive immunostaining, hematoxylin staining of distinct large nuclei, and tethered on the luminal surface
of the vessel wall (vector arrow). Infiltrated monocytes/macrophages were F4/80-positive cells that localize in the media of the vessel wall. H, summary of
F4/80-positive cells shown in G, n  5. I, representative F4/80 immunostaining of carotid artery cross-sections from iPLA2 knock-out mice (KO) and WT
littermates (WT) at 3 days after ligation. J, summary of F4/80-positive cells shown in I, n  5. *, p  0.05; **, p  0.01; ***, p  0.001 versus sham in A–E or WT in
H and J. †, p  0.05; ††, p  0.01; †††, p  0.001 versus WT/injury in A–E. NS, no significance.
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Macrophage vascular infiltrationwas also examined at 3 days
after carotid artery ligation in iPLA2-null mice and their WT
littermates (Fig. 4, I and J), and the number of macrophages
attached to the vessel wall was reduced in the former, although
the number of macrophages that had infiltrated the vessel wall
did not differ between those two genotypes.
Effects of smooth muscle-specific expression of iPLA2 on
VSMC proliferation in vivowere examined by immunostaining
for the proliferation marker PCNA in carotid arteries from
SM-iPLA2-Tg mice and their WT littermates at 3 days after
ligation. The supplemental Fig. 5A illustrates that smoothmus-
cle-specific expression of iPLA2 had no effect on PCNA
immunostaining in nonligated vessels, but it was associated
with a dramatic increase in PCNA immunostaining in ligated
carotid arteries. VSMC migration and proliferation were also
examined in aortic explants in fibrin gels. Representative
micrographs andquantitative data illustrate that at least 10-fold
more SMA-positive cells migrated and/or proliferated from
vessel explants from SM-iPLA2-Tg mice compared with their
WT littermates (supplemental Fig. 5, B and C).
12/15-Lipoxygenase Is Selectively Coupled to iPLA2 in Ang II-
and AA-induced IL-6 mRNA Expression in Cultured VSMC—
Results described so far demonstrate that smooth muscle-spe-
cific expression of iPLA2 is involved in the initiation and early
progression of vascular inflammation and neointima formation
in a murine carotid artery ligation model, but they do not iden-
tify the molecular mechanisms underlying these events.
To address these issues, we examined whether iPLA2 is
involved in Ang II-induced IL-6 mRNA expression in cultured
rat aortic VSMC. A dramatic increase in IL-6 mRNA expres-
sion was observed in VSMC treated with Ang II compared with
unstimulated cells (Fig. 5A). Pretreatment of VSMC with BEL
potently inhibited Ang II-induced IL-6mRNAup-regulation in
a concentration-dependent manner.
To ensure that the effect of BEL on Ang II-induced IL-6
mRNAexpression is attributable to inhibition of iPLA2, rather
FIGURE 5. Effects of inhibiting the iPLA2/COX/LO/CYP pathway on Ang II- or AA-induced IL-6 mRNA expression in cultured VSMC. Rat aortic VSMC (A,
B, D, and E) and mouse aortic VSMC (C and F) were pretreated with various inhibitors for 30 min and/or stimulated with Ang II (100 nM, 1 h) or AA (10 M, 1 h).
A, effects of inhibiting iPLA2 with various concentrations of BEL on Ang II-induced IL-6 mRNA expression. B, effects of iPLA2 antisense or sense oligonucleo-
tides on Ang II-induced IL-6 mRNA expression. C, effects of genetic deletion of iPLA2 on Ang II-induced IL-6 mRNA expression. D, effects of COX2 inhibitor
indomethacin (indo, 50 M), LO inhibitor nordihydroguaiaretic acid (NDGA) (30 M), and CYP inhibitor 17-octadecynoic acid (10 M) on AA-induced IL-6 mRNA
expression. E, effects of 5-LO inhibitor MK886 (1 M), P-12-LO inhibitor baicalein (10 M), and 12/15-LO inhibitor luteolin (50 M) on AA-induced IL-6 mRNA
expression. F, effects of genetic deletion of 12/15-LO on AA-induced IL-6 mRNA expression. Results are expressed as mean  S.E. from at least three indepen-
dent experiments. **, p  0.01; ***, p  0.001 versus basal in A–C, or vehicle (Veh, Me2SO2) in D–F. †††, p  0.001 versus Ang II only in A. NS, no significance versus
antisense/basal in B or iPLA2-KO/basal in C.
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than to another BEL-sensitive enzyme (34), rat aortic VSMC
were preincubated with a well characterized iPLA2 antisense
oligonucleotide that effectively suppresses iPLA2 expression
(16, 17, 20–22). Fig. 5B illustrates that the iPLA2 antisense
oligonucleotide, but not the corresponding sense oligonucleo-
tide, abolished Ang II-induced IL-6 mRNA up-regulation.
The role of iPLA2 in Ang II-induced IL-6 mRNA up-regu-
lation was also examined in aortic VSMC isolated from iPLA2
knock-out mice andWT littermates. Fig. 5C demonstrates that
Ang II-induced IL-6 mRNA expression was also markedly sup-
pressed in iPLA2-deficientmouse VSMC comparedwithWT.
The products of iPLA2 action on phospholipids include a
free fatty acid (e.g.AA) and a 2-lysophospholipid (e.g. LPC). AA
can be further metabolized to a variety of biologically active
eicosanoids via lipoxygenases (LO), cyclooxygenases (COX),
and cytochrome P450-dependent epoxygenases (CYP) (15). To
determine whether AA itself or an AAmetabolite is involved in
Ang II-induced and iPLA2-mediated IL-6 mRNA expression,
VSMC were pretreated with the LO inhibitor nordihydroguai-
aretic acid, the COX inhibitor indomethacin, or the CYP inhib-
itor 17-octadecynoic acid, respectively, before addition of AA.
We used AA rather than Ang II as a stimulus because ago-
nist-induced AA release is largely mediated by iPLA2 in
VSMC (21–23), and Ang II simultaneously activates multiple
intracellular signaling pathways in VSMC, which makes it dif-
ficult to evaluate whether the iPLA2 activation pathway is
solely responsible for subsequent events. Fig. 5D shows that
incubation of rat aortic VSMC with AA did induce a marked
rise in IL-6 mRNA levels. Pretreating the cells with the LO
inhibitor nordihydroguaiaretic acid completely prevented this
response to AA, but the COX inhibitor indomethacin and the
CYP inhibitor 17-octadecynoic acid hadno effect. This suggests
that AAmetabolism by the LO pathway but not by the COX or
CYP pathways is involved in Ang II-induced accumulation of
IL-6 mRNA in cultured VSMC.
Of the LO isozymes, rat aortic VSMC express 5-LO, platelet-
type 12-LO (P-12-LO), and leukocyte-type 12-LO (L-12-LO,
which is highly homologous to human and rabbit 15-LO) (20).
To determine which of these LO enzymes is involved in AA-in-
duced IL-6 mRNA accumulation, rat aortic VSMC were pre-
treated with MK886 (a selective 5-LO inhibitor), baicalein (a
selective P-12-LO inhibitor), or luteolin (a selective 12/15-LO
inhibitor) (16, 20, 24), before addition ofAA. Luteolin abolished
AA-stimulated IL-6 mRNA accumulation, but baicalein and
MK886 had no effect (Fig. 5E).
The potential role of 12/15-LO in AA-induced IL-6 gene
transcription was also examined in aortic VSMC from 12/15-
LO-null mice, which exhibited no rise in IL-6 mRNA levels
upon incubation with AA, although basal levels were similar to
WT.Thus, results from studies involving pharmacological inhi-
bition and genetic ablation of 12/15-LO suggest that metabo-
lites from that pathway produced from AA released by iPLA2
are involved in the signaling pathway through which Ang II
stimulates IL-6 mRNA accumulation in VSMC.
Role of iPLA2 and 12/15-LO in TNF--induced TNF- and
IL-6 mRNA Expression in Cultured VSMC—To determine
whether iPLA2 and 12/15-LO are involved in proinflamma-
tory cytokine production by VSMC in response to other ago-
nists, rat aortic VSMCwere incubated with TNF-. TNF-was
selected because TNF- is markedly up-regulated in carotid
arteries 3 days after ligation (Fig. 4F) and is implicated in
neointima formation in response to carotid artery ligation (39).
An approximate 5-fold increase was found in iPLA2 specific
activity in cells stimulated with TNF- as compared with
unstimulated cells (Fig. 6A).
TNF--induced iPLA2-specific activity (Fig. 6A) is associ-
ated with its dramatic effect on TNF- mRNA accumulation
(Fig. 6B). To determine whether iPLA2 and 12/15-LO are
required for TNF--induced TNF- mRNA accumulation, rat
aortic VSMCwere pretreated with the iPLA2 inhibitor BEL, the
12/15-LO inhibitor luteolin (Fig. 6B), and the iPLA2 antisense
oligonucleotide (Fig. 6C), respectively. It was found that inhib-
iting iPLA2 with BEL or antisense oligonucleotide and inhib-
iting 12/15-LO with luteolin markedly suppressed TNF--in-
duced TNF- mRNA accumulation.
The effect of iPLA2 on TNF--induced TNF- mRNA
accumulation was also examined in mouse aortic VSMC iso-
lated from iPLA2-null mice andWT littermates. TNF- could
potently stimulate TNF- mRNA expression in mouse aortic
WTVSMC, but this response was also significantly suppressed
in iPLA2-deficient cells (Fig. 6D). These results indicate that
the iPLA2/12/15-LO pathway is involved in TNF--induced
accumulation of TNF- mRNA in VSMC.
TNF- was also found to strongly stimulate IL-6 mRNA
accumulation in rat aortic VSMC (Fig. 6E), and this response
was also suppressed by the iPLA2 inhibitor BEL (Fig. 6E), by
iPLA2 antisense oligonucleotide (Fig. 6F), by iPLA2 genetic
deletion (data not shown), or by the 12/15-LO inhibitor luteolin
(Fig. 6E). These results suggest that the iPLA2/12/15-LOpath-
way may serve as a common component of a signaling network
governing production of inflammatory cytokines by VSMC.
VSMC iPLA2 Expression Varies with Phenotypic State and
Increases in Response to TNF-—Immunohistological analyses
of control nonligated carotid arteries in supplemental Fig. 1,
A–D suggest that healthy VSMC with a contractile phenotype
express only low levels of iPLA2. Examination of iPLA2 pro-
tein expression levels in early and late passage VSMC isolated
from mice, rats, and rabbits revealed that in each species
iPLA2 protein expression levels were higher in late passage
than in early passage VSMC (Fig. 7A). In contrast, expression
levels of the contractile proteins SM22 and SMAwere lower
in late passage than in early passage VSMC. These results sug-
gest that the iPLA2 protein expression level of the VSMC var-
ies with the phenotypic state of the cells.
To investigate the mechanism that may underlie iPLA2
up-regulation in late passage VSMC, we cloned a 0.952-kb
mouse iPLA2 promoter from a bacterial artificial chromo-
some clone and examined iPLA2 promoter activity in early
and late passage rat aortic VSMC. We found that iPLA2
promoter activity in late passage VSMC was about 3-fold
higher than that in early passage VSMC (Fig. 7B). This result
suggests that transcriptional up-regulation of iPLA2 is, at
least in part, responsible for the rise in iPLA2 protein levels
in late passage VSMC.
Proinflammatory cytokines are known to be able to alter the
VSMC phenotype (9). To explore the possibility that such
iPLA2, Vascular Inflammation, and Neointima Formation
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effects include regulation of iPLA2 expression, rat aortic
VSMC were incubated with and without TNF-. As illustrated
in Fig. 7, C and D, TNF- did cause an increase in VSMC
iPLA2 protein levels.
DISCUSSION
Although iPLA2 was once thought to serve as a housekeep-
ing enzyme involved in phospholipid remodeling (40), subse-
quent evidence from our laboratory (16, 19, 20, 24), and many
others (13, 14, 41), over the last 15 years has demonstrated that
iPLA2 expression is regulated and that it can be activated in
response to a variety of physiological stimuli in a number of cell
types. Moreover, it is now clear that iPLA2 participates in
signaling pathways that underlie processes that include insulin
secretion, cell proliferation, apoptosis, gene expression, Ca2
influx, and Ca2 sensitization of vascular smooth muscle con-
traction (13, 14, 41). Importantly, alterations of iPLA2 expres-
sion or activity have been linked to many human diseases,
including cancer, diabetes, neurodegenerative disorders, and
Barth syndrome (an X-linked cardioskeletal myopathy) (13, 14,
41).
To examine the role of iPLA2 in vascular physiological and
pathophysiological processes, we have created a transgenic
mouse line in which iPLA2 is overexpressed in smoothmuscle
cells. Using these mice in conjunction with other approaches
that include pharmacological inhibition of iPLA2 activity,
suppression of iPLA2 expression with antisense oligonucleo-
tides, and genetic deletion with iPLA2-null mice, we have
revealed a previously unrecognized role for iPLA2 in vascular
inflammation and neointima formation in a carotid artery liga-
tion model. We have found that vascular expression of iPLA2
FIGURE 6. Effects of inhibiting iPLA2 or 12/15-LO on TNF--induced TNF- or IL-6 mRNA expression in cultured VSMC. Rat aortic VSMC (A–C, E, and F)
and mouse aortic VSMC (D) were pretreated with various inhibitors for 30 min and/or stimulated with TNF- (10 ng/ml) for 5 min (A) or 1 h (B–F). A, effects of
TNF- stimulation on iPLA2-specific activity. B, effects of BEL (10 M) or luteolin (50 M) on TNF--induced TNF- mRNA expression. C, effects of iPLA2
antisense or sense oligonucleotides on TNF--induced TNF- mRNA expression. D, effects of genetic deletion of iPLA2 on TNF--induced TNF- mRNA
expression. E, effects of BEL (10 M) or luteolin (50 M) on TNF--induced IL-6 mRNA expression. F, effects of iPLA2 antisense or sense oligonucleotides on
TNF--induced IL-6 mRNA expression. Results are expressed as mean  S.E. from at least three independent experiments. *, p  0.05; ***, p  0.001 versus basal.
†††, p  0.001 versus vehicle (Veh, Me2SO2) in B and E or sense/TNF- in C and F. NS, no significance.
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protein increases markedly in response to carotid artery liga-
tion and that this precedes the neointima formation (Fig. 1,
A–C; supplemental Fig. 1, A–D).
Upon vascular injury, the concentrations of many molecules
that promote neointima formation increase in the lesion site
(1). Among them, TNF- is of particular interest because in
mice that lack functional TNF-, the area of neointima formed
in response to carotid artery ligation is 14-fold lower than that
of WT controls (39). In addition, TNF- stimulates iPLA2
activity in adult rat ventricularmyocytes (42). Here, we demon-
strate that expression of TNF- and iPLA2 increases in a tem-
porally and spatially related manner in carotid arteries 3 days
after ligation (Fig. 4F and supplemental Fig. 1,A–D). Incubation
of VSMC with TNF- in culture induces increased expression
of iPLA2 activity and protein (Figs. 6A and 7, C andD), which
suggests that TNF- might also increase iPLA2 expression in
vivo. This would represent a novel mechanism by which proin-
flammatory cytokines influence neointima formation through a
signaling pathway that involves iPLA2.
Our studies also demonstrate expression of TNF- itself is
increased in response to TNF- via a signaling pathway that
involves iPLA2 (Figs. 4, A and F, and 6, B–D). This is a poten-
tially important finding because it suggests the existence of a
positive feedback loop that is initiated by proinflammatory
cytokines such as TNF-, perhaps derived from endothelial
cells or infiltrating leukocytes, followed by activation of iPLA2
inVSMC, and then resulting in robust TNF-production. Such
a positive feedback loop could explain why TNF- and iPLA2
are up-regulated coordinately, and these could be pivotal events
in the initiation and early progression of vascular inflammation.
The mechanism by which iPLA2 protein expression is up-
regulated in response to carotid artery ligation has not yet been
elucidated. In particular, information regarding regulation of
iPLA2 gene transcription levels in VSMC and vascular endo-
thelial cells is limited. In cultured Chinese hamster ovary
(CHO) cells, Seashols et al. (43) cloned a 1-kb human iPLA2
promoter and demonstrated that sterol regulator element-
binding protein-2 (SREBP-2) binds to the iPLA2 promoter
and is responsible for sterol depletion-induced stimulation of
iPLA2 promoter activity. In cultured pancreatic islet -cells,
Lei et al. (44) reported that both basal and thapsigargin-induced
iPLA2 expression is suppressed by a dominant negative
SREBP-1 mutant. In cultured VSMC, we reported that iPLA2
mRNA is up-regulated in response to high concentrations of
glucose in a time-dependent manner (20). A report by Zhou et
al. (45) that SREBP-1 protein expression is enhanced in the
injured vascular wall, especially within the neointima, and co-
localizes with SMA-positive cells raises interest in the possi-
bility that SREBP is involved in increased iPLA2 expression in
response to carotid artery ligation. It is tempting to speculate
that carotid artery ligation may lead to increased SREBP-1
expression that in turn causes an increase in iPLA2 mRNA
expression, and this possibility deserves further examination in
the future.
It is of interest that smooth muscle-specific expression of
iPLA2 alone is insufficient to induce neointima formation
(Fig. 3A), proinflammatory cytokine production (Fig. 4, A–F),
or macrophage infiltration (Fig. 4,G andH). These results sug-
gest that iPLA2 remains inactive in the absence of vascular
injury. Some cytosolic proteins, e.g. calmodulin, can interact
with iPLA2 tomaintain its inactive state, and some stimuli, e.g.
FIGURE 7. iPLA2 protein expression levels are higher in late passage
than in early passage VSMC and can be further up-regulated by TNF- in
cultured VSMC. A, representative Western blots show expressions of iPLA2,
SM22, SMA, and GAPDH in cultured early and late passage aortic VSMC
isolated from mice (5 passage versus 10 passages), rats (1 passage versus 9
passages), and rabbit (2 passage versus 9 passages). E, early passage; L, late
passage. B, summary of a 0.952-kb mouse iPLA2 promoter activity in cul-
tured early and later rat aortic VSMC (2 passage versus 9 passages). ***, p 
0.001 versus early passage VSMC. C, representative iPLA2 Western blots from
rat aortic VSMC stimulated with or without TNF- (10 ng/ml, 24 h). D, quanti-
tative data shown in C. n  8.
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thapsigargin, induce release of iPLA2 from the calmodulin-
iPLA2 complex to activate iPLA2 (18, 46). It is therefore pos-
sible that increased TNF- levels may result in iPLA2 activa-
tion through a mechanism that involves disassociation of an
inhibitory complex. This may explain why both carotid artery
ligation and increased expression of iPLA2 in smooth muscle
cells are required for development of vascular inflammation
and neointima formation in SM-iPLA2-Tg mice.
Perhaps the most novel finding from this study is that we
demonstrate that activation of iPLA2 in VSMC in response to
carotid artery ligation is involved in the initiation and early
progression of vascular inflammation. Several independent
lines of evidence support this conclusion. First, in the absence
of neointima formation, iPLA2, TNF-, and IL-6 protein lev-
els increase in a temporally and spatially coordinatedmanner in
response to carotid artery ligation (supplemental Figs. 1, A–D,
and 4A and 4F ). Second, smooth muscle-specific expression of
iPLA2 results in increased levels of mRNA for several proin-
flammatory cytokines (Fig. 4,A–E). Third, smoothmuscle-spe-
cific expression of iPLA2 elevates TNF- and IL-6 proteins in
the absence of neointima formation (Fig. 4F; supplemental Fig.
4A). Fourth, macrophage infiltration, which is a hallmark of
early vascular inflammation, is enhanced by smooth muscle-
specific expression of iPLA2 (Fig. 4,G andH) and is attenuated
in vessels from iPLA2-null mice (Fig. 4, I and J). Finally, inhi-
bition of iPLA2 activity with BEL, suppression of iPLA2
expression with antisense oligonucleotide, and genetic deletion
of iPLA2 each resulted in suppression of accumulation of
mRNA for IL-6 and TNF- in VSMC in response to incubation
with Ang II or TNF- (Figs. 5, A–C, and 6, B–F).
We have previously demonstrated that, in cultured VSMC,
12/15-LO is downstream of iPLA2 in the signaling pathways
underlying Ang II-induced RGS2 transcriptional activation
(16) and cAMP-response element-binding protein phosphory-
lation (24) and RhoA/Rho-kinase/CPI-17 phosphorylation
induced by incubationwith high concentrations of glucose (20).
Consistent with those reports, our current studies illustrate
that 12/15-LO is also a component downstream of iPLA2 in a
signaling pathway that underlies increases in levels of mRNA
for IL-6 and TNF- in VSMC incubated with AA or TNF-
(Figs. 5, D–F, and 6, B and E).
Consistent with a role for 12/15-LO in production of proin-
flammatory cytokines, Natarajan et al. (47) reported that the
12/15-LO product hydroperoxyoctadecadienoic acid is a
potent stimulator of NFB activity in primary cultured porcine
VSMC. Dwarakanath et al. (48) reported that hydroper-
oxyoctadecadienoic acid causes increased transcription of the
MCP-1 andTNF- genes in cultured humanVSMC in anNFB
p65-dependent manner. Similarly, Chava et al. (49) reported
that the 12/15-LO product hydroxyeicosatetraenoic acid stim-
ulates IL-6mRNAaccumulation in primary cultured rat VSMC
in a cAMP-response element-binding protein-dependentman-
ner. Concordant with those reports, our current studies dem-
onstrate that smooth muscle-specific expression of iPLA2
results in a marked increase in NFB p65 protein immuno-
staining in response to carotid artery ligation (supplemental
Fig. 4B), which suggests that NFB p65may serve as a common
transcriptional factor that links the iPLA2/12/15-LO signaling
pathway to production of multiple proinflammatory cytokines,
although the detailed mechanism by which this pathway leads
to NFB p65 is the subject of ongoing inquiry.
A role for iPLA2 in vascular inflammation has not been well
recognized previously. An early study byWalev et al. (50) indi-
cated that the iPLA2 inhibitor BEL diminishes LPS-induced
IL-1 secretion by inhibiting the inflammasome in mononu-
clear cells, but a more recent study by Franchi et al. (51) dem-
onstrated that this is an off-target effect of BEL that does not
result from iPLA2 inhibition. Whether iPLA2 is involved in
transcriptional regulation of IL-1 or other proinflammatory
cytokines is a question that has been largely unexplored in any
cell type.
Our findings that iPLA2 is involved in proinflammatory
cytokine production in VSMC provides new insight into inter-
actions among cellular participants in vascular inflammation,
which has long been thought to involve mainly monocytes/
macrophages, other leukocytes, and endothelial cells, despite
the fact that VSMC can also produce proinflammatory cyto-
kines both in vitro and in vivo (7–9) and that this could be a
significant source of cytokines in view of the large number of
VSMC in the vascular wall. Evidence from our current studies
indicates that VSMC are not merely passive responders to sig-
nals from macrophages or endothelial cells but rather actively
interact with other cells in the vascular wall and participate in
proinflammatory cytokine production in a coordinatedmanner
that leads to the initiation and early progression of vascular
inflammation.
Involvement of iPLA2 in cell proliferation has been demon-
strated in several types of cultured cells (41), including VSMC
(17, 23), but there has been little attention to this issue in animal
models that aremore relevant to physiological and pathological
processes in vivo. Our current studies are the first of which we
are aware to address these issues with four independent lines of
investigation that include the following: 1) pharmacological
inhibition of iPLA2 with BEL (Fig. 1, D and E); 2) suppression
of iPLA2 expression with antisense oligonucleotides (Fig. 1, F
andG); 3) genetic deletion of iPLA2 by homologous recombi-
nation in iPLA2-null mice (Fig. 1, H and I); and 4) smooth
muscle-specific expression of iPLA2 (Fig. 3, A–E; supplemen-
tal Fig. 5, A and B). Findings from each approach are comple-
mentary and consistently indicate that iPLA2 plays a critical
role in neointima formation.
The pharmacological iPLA2 inhibitor BEL used in our in
vitro and in vivo experiments has off-target effects that include
inhibition of other serine lipases (34), serine proteases (51), and
a number of other enzymes (35). Conclusions based on exper-
iments involving BEL thus require confirmation by experi-
ments from independent lines of investigation. Although
iPLA2 global knock-out mice and iPLA2 antisense oligonu-
cleotides are generally thought to be more specific than BEL,
such reagents do not discriminate among cell types. Smooth
muscle cell-specific iPLA2 transgenic mice that are described
here are useful in that regard, but there is always the concern of
whether overexpressed iPLA2 is same as endogenous iPLA2.
Conditional iPLA2 knock-out mice that selectively fail to
express iPLA2 only in smooth muscle cells are required to
clarify these issues.
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In summary, our results demonstrate that activation of
iPLA2 in VSMC is involved in the initiation and early progres-
sion of vascular inflammation and neointima formation in a
mouse carotid artery ligation model. Fig. 8 summarizes a
model that integrates our major findings and experimental
approaches and proposes a sequence of biochemical events in
VSMC signaling pathways. Activation of iPLA2 by carotid
artery ligation is proposed to liberate AA that is metabolized by
the 12/15-LO enzyme to produce eicosanoid mediators that
elicit a train of events that lead to production of inflammatory
cytokines, infiltration of macrophages into the vascular wall,
proliferation of VSMC, formation of neointima, and stenosis or
restenosis of the vessel to produce luminal compromise or
occlusion. Our results indicate that smooth muscle iPLA2
may represent a novel therapeutic target for development of
new therapeutic agents to attenuate or prevent such vaso-oc-
clusive events in human cardiovascular diseases.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Coimmunofluorescence − Ligated and non-ligated carotid arteries were isolated at 3 days after ligation 
from 10 week-old C57BL/6 mice, snap-frozen by quenching in liquid nitrogen, and embedded in Tissue-
Tek O.C.T. (Fisher Scientific). 10 µm thickness cross cryosections of carotid arteries were dried at room 
temperature (RT) for 20 min before they were fixed by chilled 4% formaldehyde in 150 mM sodium 
phosphate buffer (PH 7.4) for 30 min. Sections were then blocked with 5% normal goat serum in PBS at 
RT for 1 hour. Sections were incubated with a rabbit anti-iPLA2β polyclonal Ab (1:50 dilution) that was 
generated by our laboratory as described (1) at 4°C over night. Sections were washed and then incubated 
with Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, 1:100) at RT for 30 min. Sections were washed 
and then incubated with the following Abs in blocking buffer at RT for 1 hour: 1) a mouse monoclonal 
anti smooth muscle α-Actin (SMαA, Sigma-Arldrich, 1:100); 2) a rat anti-mouse CD31 (BD pharmagen, 
1:50); 3) a rat anti-mouse F4/80 (AbD Serotec, 1:100).  After washes, sections were incubated with 
M.O.M.™ Mouse Ig Blocking Reagent (Vector Lab, Burlingame, CA) and goat anti-mouse Alexa Fluor 
594 for SMαA or goat anti-rat Alexa Fluor 594 (Invitrogen) for CD31 and F4/80 at RT for 30 min. 
Sections were then stained with DAPI nuclear counterstain at RT for 3 min. Sections were mounted in 
glycerol gelatin (Sigma) and photographed by Olympus IX70 microscope as described (2). 
 
Aortic Explant Culture – Aortas were isolated from iPLA2β-Tg mice and WT littermates. After removal 
of blood, fibroadipose tissue and endothelial cells, the aortas were cut into 2 mm2 explants using a ruler 
under dissection microscope. The aortic explants were placed in a 12-well tissue culture dish containing 
15 μl thrombin (0.15 U, Sigma) and 300 μl clotting media (0.3% fibrinogen, 0.5% -amino-n-caproic acid, 
50 mg/ml gentamicin (Sigma) in Medium 199 (Invitrogen). The gel was allowed to clot at 24°C for 60 
minutes. An equal volume of normal VSMC growth medium (10% FBS in DMEM supplement with 
ampicillin and streptomycin) was added. The aortic explants were then placed in cell culture incubator. 
The aortic explants were photographed at day 3, 5, 7, and 14 by Olympus IX70 microscope. The migrated 
cells were immunostained with an anti-SMαA Ab and over 95% of cells are positive (data not shown). 
The area of migrated VSMC was traced and analyzed with Olympus MicroSuit™-B3 software. 
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SUPPLEMENTARY FIGURE LEGEND 
 
Supplemental Figure 1. Increased iPLA2β protein expression largely colocalizes with the smooth 
muscle α-actin and inhibiting iPLA2β with BEL or antisense oligonucleotide inhibits neointima 
formation. (A) non-ligated (sham) and ligated (injury) carotid arteries were isolated from C57BL/6J mice 
at 3 days after ligation, and then subjected to iPLA2β antibody immunostaining. Representative 
photographs show that iPLA2β immunostaining (brown color) is evident in the tunica media of injured 
carotid arteries. (B through D) Non-ligated (sham) and ligated (injury) carotid arteries were isolated from 
C57BL/6 mice at 3 days after ligation, embedded in O.C.T., and then were subjected to 
coimmunostaining with the antibody against iPLA2β with the antibodies against smooth muscle cell 
marker SMαA, the endothelial cell marker CD31, and monocyte/macrophage marker F4/80. iPLA2β 
immunostainings (B-D, images iii and iv, red color) were merged with SMαA (B, image i and ii, green 
color), CD31 (C, images i and ii, green color), and F4/80 (D, images i and ii, green color), respectively, 
showing that iPLA2β largely colocalized with SMαA (B, images vi and viii) although some iPLA2β was 
also found to colocalize with CD31 (C, images vi and viii) and  monocyte/macrophage marker F4/80 (D, 
images vi and viii). Of note, DAPI was used as a nuclear counter-stain (blue color) and the white square 
in images v and vi in (B-D) at lower magnification (LM) indicates the region photographed at higher 
magnification (HM) in images vii and viii in (B-D). (E) A schematic diagram shows local delivery of 
BEL or antisense oligonucleotide to carotid arteries by pluronic gel. (F) A schematic diagram outlines a 
serial of sequential cross-sections. Carotid arteries were cut in serial sections of 5 μm thickness. 4 
sections that are 200 μm apart and cover 1,000 μm to 1,800 μm along the carotid artery from the ligation 
site were collected for morphometric and immunostaining analysis. (G) Representative Verhoeff-Van 
Gieson elastin staining of paraffin cross-sections shows that 28-day carotid ligation markedly induced 
neointimal formation, and inhibiting iPLA2 by pluronic gel-mediated perivascular delivery of BEL, but 
not vehicle (Me2SO2), inhibits neointima formation at 28 days after ligation. (H) Representative Verhoeff-
Van Gieson elastin staining of paraffin cross-sections shows that inhibiting iPLA2β by pluronic gel-
mediated perivascular delivery of iPLA2β antisense oligonucleotide, but not sense oligonucleotide, 
inhibits neointima formation at 14 days after ligation. All experiments were repeated at least three times. 
 
Supplemental Figure 2.  iPLA2β is expressed specifically in smooth muscle cells in various vascular or 
visceral smooth muscle tissues from SM-iPLA2β mice. Representative photographs show that exogenous 
iPLA2β protein, as indicated by immunostaining of cross-cryosections with a specific FLAG antibody 
(red color), is selectively expressed in smooth muscle cells in vascular smooth muscle tissues (coronary 
artery, renal artery, carotid artery, and aorta) and visceral smooth muscle tissues (bladder, rectum, and 
ileum). Experiments were repeated at least three times. 
 
Supplemental Figure 3. Effects of smooth muscle-specific expression of iPLA2β on lumen area, total 
vessel area, and media area. Carotid arteries were collected from SM-iPLA2β-Tg mice (Tg) and WT 
littermates at 28 days after carotid ligation, and then subjected to morphometric analysis. Summary of 
lumen area (A), total vessel area (B), and media area (C) from 20 sections that cover 500 µm to 2,500 µm 
along the carotid artery from the ligation site. Results were analyzed by 2-way ANOVA analysis. 
 
Supplemental Figure 4. Smooth muscle-specific expression of iPLA2β exacerbates carotid ligation-
induced IL-6 and NFκB p65 protein expression. Ligated (injury) and non-ligated (sham) carotid arteries 
were collected from SM-iPLA2β-Tg mice (Tg) and WT littermates (WT) at 3 days after carotid ligation, 
and then subjected to immunocytochemistry. Representative photographs show that IL-6 (A) or NFκB 
p65 (B) immunostainings in SM-iPLA2β-Tg mice (brown color) are more evident than that in WT 
littermates. All experiments were repeated at least three times. 
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Supplemental Figure 5. Smooth muscle-specific expression of iPLA2β promotes VSMC proliferation in 
vivo and ex vivo. (A) Carotid arteries were isolated from SM-iPLA2β-Tg mice (Tg) and WT littermates 
(WT) at 3 days after carotid ligation, and then subjected to PCNA immunostaining. Representative 
photographs show that PCNA immunostaining in SM-iPLA2β-Tg mice (brown color) was more evident 
than that in WT littermates. (B) Aortas were collected from SM-iPLA2β-Tg mice (Tg) and littermates 
(WT) and then cultured for 7 days. Representative SMαA immunostaining shows that 
migrated/proliferated cells from explanted aortas are VSMC, and more cells migrated/proliferated from 
SM-iPLA2β-Tg mice than that from littermates. (C) Summary of results shown in (B).  Results are 
expressed as mean ± SEM of areas that are covered by migrated SMC from 10 segments of aorta. All 
experiments were repeated at least three times. *, P<0.05. 
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